0.2593  0.004 (1.49%)		08-18 10:32
Open: 0.258 High: 0.2638 Volume: 21,022		Pre. Close: 0.2555 Low: 0.2563 Market Cap: 11(M)

Short term
Mid term
Targets	6-month :	0.34	1-year :	0.39
Resists	First :	0.29	Second :	0.34
Pivot price	0.27
Supports	First :	0.22	Second :	0.18
MAs	MA(5) :	0.26	MA(20) :	0.27
	MA(100) :	0.68	MA(250) :	0.85
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	29.5	D(3) :	36.2
RSI	RSI(14): 28.6
52-week	High :	1.45	Low :	0.22

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ AEON ] has closed above bottom band by 24.6%. Bollinger Bands are 76.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 12 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	0.28 - 0.28	0.28 - 0.28
Low:	0.25 - 0.25	0.25 - 0.26
Close:	0.25 - 0.26	0.26 - 0.26

AEON Biopharma, Inc. is a biopharmaceutical company primarily engaged in developing therapies based on botulinum toxins, aimed at treating various debilitating medical conditions. Among its key investigational products is ABP-450, a 900 kDa botulinum toxin complex, which is being advanced for therapeutic use in conditions such as migraine, cervical dystonia, and gastroparesis. The entity, originally known as ALPHAEON Corporation, adopted the name AEON Biopharma, Inc. in December 2019. Established in 2012, the company maintains its principal operations from Newport Beach, California.

Mon, 17 Aug 2026
H.C. Wainwright cuts Aeon Biopharma stock price target on dilution - Investing.com

Wed, 12 Aug 2026
AEON Biopharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times

Wed, 12 Aug 2026
AEON Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com

Mon, 03 Aug 2026
AEON Biopharma Raises About $13.6M Net, Regains Listing Compliance - Stock Titan

Mon, 03 Aug 2026
AEON Biopharma Regains NYSE American Compliance After Completing Public Offering - quiverquant.com

Mon, 03 Aug 2026
AEON Biopharma (NYSE American: AEON) lifts .BC indicator after $13.6M equity raise - Stock Titan

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: AMEX
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	0 (M)
Held by Insiders	0 (%)
Held by Institutions	0 (%)
Shares Short	0 (K)
Shares Short P.Month	0 (K)

EPS	0
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	0 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	0
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	0

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.